Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM27M plus osimertinib in EGFR-mutant advanced non-squamous NSCLC after EGFR-TKI failure
CTR20252840Phase 2Active
- Sponsor
- ImmuneOnco
- Start
- Jul 2025
- Modality
- Small Molecules, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of IMM27M and osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ImmuneOnco. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started Jul 2025; status: active.
02
Drugs
IMM27Mosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252840.